What are the side effects of exogenous pulmonary surfactant in neonates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Side Effects of Exogenous Pulmonary Surfactant in Neonates

Surfactant administration procedures may be complicated by transient airway obstruction, oxygen desaturation, bradycardia, and alterations in cerebral blood flow and brain electrical activity during the delivery process. 1

Acute Administration-Related Complications

The most common adverse effects occur during or immediately after surfactant instillation and are typically transient:

Immediate Procedural Complications

  • Airway obstruction - transient blockage during bolus administration
  • Oxygen desaturation - drops in SpO2 requiring brief intervention
  • Bradycardia - heart rate drops during administration
  • Endotracheal tube reflux - surfactant backing up into the tube (more common with infusion technique versus bolus) 1, 2
  • Alterations in cerebral blood flow and brain electrical activity - hemodynamic changes during administration 1

Post-Administration Risks

Rapid improvement in lung mechanics creates secondary risks that require immediate ventilator adjustments:

  • Lung injury and air leak - can occur if ventilator settings are not expeditiously reduced after surfactant improves lung compliance, functional residual capacity, and lung volume 1
  • Pneumothorax and pulmonary interstitial emphysema - though surfactant overall reduces these complications compared to no treatment, inadequate ventilator management post-administration increases risk 1

Uncommon but Serious Adverse Effects

Pulmonary Hemorrhage

Pulmonary hemorrhage is the most concerning adverse effect, though it remains infrequent. This complication appears more often in surfactant-treated infants compared to controls, though the absolute incidence remains low 3, 4. The mechanism may relate to rapid changes in pulmonary blood flow and left-to-right ductal shunting.

Hemodynamic Effects

  • Increased left-to-right ductal shunt - can occur due to rapid improvement in lung compliance 4
  • Hemodynamic effects are generally less striking than the respiratory improvements

Long-Term Safety Profile

Surfactant replacement has not been shown to affect the incidence of neurologic, developmental, behavioral, medical, or educational outcomes in preterm infants - the long-term safety profile is reassuring 5, 4.

Critical Management Considerations

Clinicians with expertise in surfactant administration procedures should be responsible for surfactant delivery whenever it is given 1. This requirement exists because:

  1. Vigilant monitoring is essential during and immediately after administration 2
  2. Expeditious ventilator adjustments must be made to prevent barotrauma once lung mechanics improve 1
  3. Recognition and management of acute complications requires specialized neonatal expertise

Product-Specific Differences

While all surfactants can cause these effects, animal-derived surfactants (beractant, calfactant, poractant) have demonstrated lower mortality rates and fewer pneumothoraces compared to first-generation synthetic surfactants 1, 3, 4.

Surfactants requiring smaller dosing volumes may decrease the incidence of reflux, bradycardia, and desaturation 2.

Common Pitfalls to Avoid

  • Failure to reduce ventilator settings promptly after surfactant administration - this is the most preventable cause of air leak complications
  • Inadequate monitoring during the 15-30 minute period after administration when acute effects are most likely
  • Administration by inexperienced personnel without immediate access to expertise in managing complications

References

2
Research

Practical considerations in the selection and use of pulmonary surfactant therapy for neonatal respiratory distress syndrome in the intensive care setting.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2006

3
Research

Exogenous surfactant therapy in newborn infants.

Annals of the Academy of Medicine, Singapore, 2003

Related Questions

In which neonates should exogenous surfactant be administered, including gestational age, respiratory distress syndrome criteria, and conditions such as severe meconium aspiration, pulmonary hemorrhage, or persistent pulmonary hypertension?
At what stage of lung development is exogenous surfactant therapy most effective in preterm infants?
How does exogenous surfactant administration cause pneumothorax?
When does pulmonary surfactant production begin in the fetal lungs?
If a patient develops sexual adverse effects after one year of finasteride therapy, are these effects likely to resolve after stopping the medication?
Can goserelin be administered concurrently with capecitabine?
Is the treatment for posterior vitreous detachment the same as the treatment for posterior vitreous hemorrhage?
In a 10‑week pregnant patient with bacteriuria (14 /HPF), pyuria (leukocytes 12.21 ×10³/µL), neutrophilia (absolute neutrophil count 8.79 ×10³/µL) and a single fever episode of 38.4 °C, should she be treated with medication?
What is the definition of fever of unknown origin (FUO) in children and how should it be evaluated?
How does hydrofluoric acid inhalational burn affect the lungs?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.